WO2019213747A1 - Muc16 monoclonal antibody and uses thereof - Google Patents

Muc16 monoclonal antibody and uses thereof Download PDF

Info

Publication number
WO2019213747A1
WO2019213747A1 PCT/CA2019/050565 CA2019050565W WO2019213747A1 WO 2019213747 A1 WO2019213747 A1 WO 2019213747A1 CA 2019050565 W CA2019050565 W CA 2019050565W WO 2019213747 A1 WO2019213747 A1 WO 2019213747A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
binding fragment
antigen
seq
cdr
Prior art date
Application number
PCT/CA2019/050565
Other languages
English (en)
French (fr)
Inventor
Ragupathy Madiyalakan
Michael A. HOLLINGSWORTH
Prakash Radhakrishnan
Original Assignee
Quest Pharmatech Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmatech Inc. filed Critical Quest Pharmatech Inc.
Priority to CN201980031339.9A priority Critical patent/CN112119095A/zh
Priority to CA3095457A priority patent/CA3095457A1/en
Priority to US17/048,119 priority patent/US11773183B2/en
Priority to EP19799414.8A priority patent/EP3790902A4/en
Publication of WO2019213747A1 publication Critical patent/WO2019213747A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/CA2019/050565 2018-05-09 2019-04-30 Muc16 monoclonal antibody and uses thereof WO2019213747A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201980031339.9A CN112119095A (zh) 2018-05-09 2019-04-30 Muc16单克隆抗体及其用途
CA3095457A CA3095457A1 (en) 2018-05-09 2019-04-30 Muc16 monoclonal antibody and uses thereof
US17/048,119 US11773183B2 (en) 2018-05-09 2019-04-30 MUC16 monoclonal antibody and uses thereof
EP19799414.8A EP3790902A4 (en) 2018-05-09 2019-04-30 MUC16 MONOCLONAL ANTIBODY AND ASSOCIATED USES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862669058P 2018-05-09 2018-05-09
US62/669,058 2018-05-09

Publications (1)

Publication Number Publication Date
WO2019213747A1 true WO2019213747A1 (en) 2019-11-14

Family

ID=68466825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2019/050565 WO2019213747A1 (en) 2018-05-09 2019-04-30 Muc16 monoclonal antibody and uses thereof

Country Status (5)

Country Link
US (1) US11773183B2 (zh)
EP (1) EP3790902A4 (zh)
CN (1) CN112119095A (zh)
CA (1) CA3095457A1 (zh)
WO (1) WO2019213747A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113969266B (zh) * 2021-10-26 2023-10-13 山东大学齐鲁医院 一种重组溶瘤腺病毒及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149368A1 (en) * 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358985B (zh) * 2013-07-09 2018-08-28 内布拉斯加大学董事会 靶向糖蛋白以治疗癌症的新方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016149368A1 (en) * 2015-03-17 2016-09-22 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIPSON I. ET AL.: "Generation and characterization of a monoclonal antibody to the cytoplasmic tail of MUC16", GLYCOBIOLOGY, vol. 27, no. 10, 1 October 2017 (2017-10-01), pages 920 - 926, XP055651609 *
MAEDA T ET AL.: "Solution structure of the SEA domain from the murine homologue of ovarian cancer antigen CA 125 (MUC16)", J BIOL CHEM., vol. 279, no. 13, 26 March 2004 (2004-03-26), pages 13174 - 82, XP055651610 *
RAO TD ET AL.: "Antibodies against specific MUC16 glycosylation sites inhibit ovarian cancer growth", ACS CHEM BIOL, vol. 12, no. 8, 18 August 2017 (2017-08-18), pages 2085 - 96, XP055651594 *

Also Published As

Publication number Publication date
EP3790902A1 (en) 2021-03-17
US20210101994A1 (en) 2021-04-08
CA3095457A1 (en) 2019-11-14
EP3790902A4 (en) 2022-02-16
CN112119095A (zh) 2020-12-22
US11773183B2 (en) 2023-10-03

Similar Documents

Publication Publication Date Title
CN109415439B (zh) 用于癌症治疗的抗pd-1和抗-lag3抗体
EP3473649A1 (en) Anti-cd47 monoclonal antibody and application thereof
WO2018133842A1 (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
JP2023098966A (ja) 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP2019521087A (ja) 抗ｃＭｅｔ抗体薬物複合体及びその使用方法
CN114026125A (zh) Cldn18.2抗体及其用途
JP2022523710A (ja) Ｃｄ４４に特異的な抗体
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
US11773183B2 (en) MUC16 monoclonal antibody and uses thereof
US11351255B2 (en) Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
CN116731169B (zh) 一种分拣蛋白1特异性的纳米抗体及其应用
WO2020221198A1 (zh) 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
EP4357362A1 (en) Bispecific antibody combination and use thereof
US10023652B2 (en) Method of targeting glycoproteins to treat cancer
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
US20230070306A1 (en) Monoclonal antibodies against her2/neu and uses thereof
WO2023021319A1 (en) Monoclonal antibodies against her2/neu and uses thereof
EP3831850A1 (en) Antibodies to programmed death ligand (pd-l1) and application thereof
WO2023023871A1 (en) Combination of an ige monoclonal antibody specific to a cancer antigen and nk cell for the treatment of cancer
EP3864039B1 (en) Neuroendocrine cancer targeted therapy
CN114456267B (zh) 一种抗cd73人源化单克隆抗体及其应用
EP4257608A1 (en) Antibody specific for cd47 and use thereof
WO2018141054A1 (en) Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
CN117440971A (zh) 具有提高的癌细胞杀灭功效的非对称抗体
JP2022501062A (ja) Ｅｐｎ１を標的とする抗体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19799414

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3095457

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019799414

Country of ref document: EP

Effective date: 20201209